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ABSTRACT
Various researches have been conducted over the recent years on the therapeutic effects
of statins on the metabolic and hyper-androgenic state of the patients suffering from PCOS. The
present research seeks to evaluate the treatment with atorvastatin and its effect on the lipid profile
level, serum androgen status and morphology and blood flow of polycystic ovaries. A double blind
clinical trial was designed for this research where the women with PCOS resorting to the gynecology
clinic of Firouzgar Hospital were randomly divided into two groups: case and Control. Early at the
beginning of the research, variables such as body mass, lipid profile, blood androgen level, fasting
blood Sugar, size of the ovary, and resistance of the stromal artery of ovary were studied. For a
period of 6 weeks, one group was given with a daily dose of 40 mg atorvastatin, while the other
group just received placebo. All the variables were studied once again after 6 weeks and the
results were analyzed using SPSS v.16. The case group included 20 patients suffering from PCOS
who received atorvastatin, while there were 20 patients with PCOS in the witness group who just
received placebo. The average ages in the atorvastatin and placebo groups were 27.7 ± 3.41 and
30.9 ± 4.8 years old respectively. A significant difference was observed between the two groups
in terms of changes in the average cholesterol and LDL levels before and after the intervention.
This reduction was more significant in the atorvastatin group. After prescription of atorvastatin, the
level of Androstenedione had decreased significantly in treatment group. A statistically significant
reduction was observed in the size of left and right ovaries in the group receiving atorvastatin. No
significant changes were observed in the size of the ovaries in the group receiving placebo. The
average arterial resistance level of left and right ovaries before and after intervention in atorvastatin
group exhibited a significant reduction. Having discarded the confounding effect of RI, this difference
with the witness group was statistically significant. Keeping in mind the effects of atorvastatin such
as improving the lipid profile status and reduction of androstenedione among those with PCOS, it
can be used as an auxiliary treatment to control symptoms and long-term side effects among
patients. Considering the shrinkage of ovary size and enhancement of blood flow to PCOS ovary,
future researches can focus on effectiveness of statins in improving the ovulation status of
performance of PCO ovaries.
Keywords: Hyper-androgenism, Arterial Performance of Ovary,
Hyperinsulinemia, Atorvastatin. PCOS.
INTRODUCTION
Polycystic ovary syndrome is a syndrome
with various symptoms and signs. It is also the most
common endocrine pathology among women
observed during the ages of fertility, but it is far from
being exclusive and hence no particular cause can
be introduced for it1. Various definintoin have been
proposed for this syndrome. According to Rotterdam
criteria, the presence of 2 of these 3 symptoms
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indicates this syndrome: 1. no or little ovulation
(Oligomenorrhea or Amenorrhea)2. hyper-
androgenomia or hyper-androgenism, and 3.
polycystic ovaries (diagnosed through sonography
and through discarding other complications with
too much discharge of androgen or correlating
complications)1. Nearly 70% of polycystic ovary
syndromes exhibit signs of the abnormal lipid levels
in body2. Women with PCOS whether fat or not
exhibit degrees of Dyslipidemia and these changes
are observed in all three levels of TG, HDL, and
LDL3. As various researches have shown, further
to reducing the lipid level of blood, atorvastatin also
helps decrease androgen4. In this syndrome, there
is a direct correlation between levels of androgen
and insulin resistance and blood lipids level.
Reducing the lipid level of blood can help improve
the androgen level and enhance Hyperinsulinemia
and reduce the side effects of this disease4. Various
researches have also pointed to the fact that
atorvastatin can help improve the blood flow of
Brachial artery1. Although no studies have ever
been conducted on this medicine and blood flow of
ovary artery, we have set to study the effect of this
medicine on ovary artery given the available
literature indicating improvement of DOMINANT
ovary and ovulation with the rise and enhancement
of blood flow of ovary artery5. Considering the
problems of those with this disease (obesity,
hyperinsulinemia, hyper-androgenomia, no
ovulation and Hirsutism), it is necessary to seek an
appropriate cure to this disease and try to enhance
the life quality of these patients.
MATERIAL AND METHOD
This is an analytical, double blind, clinical
trial research. The population includes all the
women with PCOD resorting to the clinic of
Firouzgar Hospital from November 2004 to March
2005. The patients and the measurers had no idea
of the variables associated with attribution of the
patients. The following inclusion criteria were
defined: 1) diagnosis of PCOS based upon
existence of 2 of the 3 criteria specified by
Rotterdam, 2) BMI > 25.2, 3) LDL > 100, 4) no
pregnancy, 5) no other reasons for obesity and
metabolic and hormone and glands and
metabolism issues, 6) no use of Metformin and other
medicines that create sensitivity to insulin and no
use of OCP over the last three months and no
consumption of medicines that reduce androgen,
7) no sensitivity to atorvastatin, and 8) aging 18 to
35 years old. Certain exclusion criteria were also
defined such as 1) pregnancy, 2) using metformin
or any other medicines that cause sensitivity to
insulin and OCP over the last 3 months before the
research and androgen reducer (using
progesterone for withdrawal or keeping
mensturation was ok), 3) LDL < 100, 4) BMI < 25, 5)
any hormonal or metabolic disorders not related to
PCOS, 6) any sensitivity to atorvastatin exhibited
by the rise of liver enzymes more than three times
the normal level and severe cramps of muscles.
People qualified for the research were randomly
divided into randomized blocks containing 4 people
in each one. Early at the beginning of the research,
variables such as body mass, lipid profile, blood
androgen level, fasting blood Sugar, size of the
ovary, and resistance of the stromal artery of ovary
were studied. For a period of 6 weeks, one group
was injected with a daily dose of 40 mg atorvastatin,
while the other group just received placebo. All the
variables were studied once again after 6 weeks
and the results were analyzed using SPSS v.16.
The tool to collect data was a questionnaire
asking for information such as age, LIPID PROFILE,
BMI, the androgen level of blood, size of ovary,
levels of insulin, fasting blood Sugar, and resistance
of the stromal artery of ovary. All laboratory
procedures were carried out in laboratory of
Firouzgar Hospital. Only the procedures associated
with Androstenedione hormone were undertaken
in Nour pathobiology laboratory. You will find the
kits and experiment methods and techniques used
below:
FBS: (Kit: Biosystem) (Experiment Method: Glu-
oxidase) (Technique: Auto analyzer sapphire 800)
Chol: (Kit: Biosystem) (Experiment Method: Chol-
oxidase) (Technique: Auto analyzer sapphire 800)
TG: (Kit: Biosystem) (Experiment Method:
Peroxidase) (Technique: Auto analyzer sapphire
800)
HDL: (Kit: Biosystem) (Experiment Method: Direct)
(Technique: Auto analyzer sapphire 800)
LDL: No kit and through calculation
Testosterone: By ECL machine built by Rosh
German Company
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DHEAS: By Liason machine by Rosh German
Company
Androstenedione:  (Diametra kit) (Experiment
Method: Eliza)
Vaginal Doppler and sonography were
carried out by radiologist in sonography ward of
Firouzgar Hospital. A Voluson 730 Expert machine
with a 6 to 12 MHz micro convex vaginal probe was
used for sonography. 40 mg atorvastatin pills (in
the form of calcium tri-hydrate) built by Sobhan
Darou Company registered under code
1228058660 (IRC) was used in the case group
while 100 mg pills of B1 vitamin produced by Darou
Pakhsh Co. was used as placebo for witness group
(thiamin hydrochloride). Sequential nonrandom
sampling method was used in both groups. The
resulting information was analyzed using SPSS 16.
As for qualitative variables, indicators such as
frequency, mode, mean, and average were
calculated. The frequency of qualitative variables
was also measured. Independent t test was used to
study qualitative variables, while repeated
measures test was used to calculate the changes
observed in two groups before and after
intervention. Forward linear regression was used
to study the confounding effect. The ethics
committee of Iran University of Medical Sciences
studied the ethical aspects of this research and
approved it under the code 93/D/105/4431. The
patients were not charged for experiments. The
results were confidential and only the general
results and conclusions were reported. Throughout
the stages of this research, the ethical principles
specified in treaty of Helsinki were observed. The
general results were published in credible scientific
resources in order to fulfill the goals. The written
consent of the patients was obtained before their
entrance to the research.
RESULTS
The present research was conducted to
study the effect of atorvastatin on the arterial
performance of ovary and androgen level of blood
among those suffering from polycystic ovary
syndrome. The case group included 20 patients
suffering from PCOS who received atorvastatin,
while there were 20 patients with PCOS in the
witness group who just received placebo. The
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average ages in the atorvastatin and placebo
groups were 7.27 ± 3.41 (22 to 35) and 9.30 ± 4.8
(18 to 35) years old respectively. Table 1 presents
the results of laboratory profile for all groups before
and after treatment in details.
DISCUSSION
Polycystic ovary syndrome is a kind of
syndrome with various signs and symptoms and it
is far from being an exclusive endocrine pathology,
thus it has no exclusive cause. Keeping in mind the
frequency and prevalence of this disease and the
problems caused by it in terms of hormone,
appearance, metabolism and other systematic
issues, it will turn into a major infertility problem
among those women in the age of pregnancy and
fertility. There are several researches and studies
conducted on this issue with similar or dissimilar
results in terms of the type of research and the
population studied. Based on our researches, our
paper is the first one to study the influence of
atorvastatin on the stromal artery of ovary. Of course,
similar studies using metformin have been
conducted over this issue6. Positive effects of statins
in reducing arthrosclerosis and cardiovascular
diseases have been proved. As a result, statins are
used to treat dyslipidemia and to prevent
atherosclerosis and cardiovascular issues7. The
present research also studied the possible effect of
atorvastatins in reducing the sclerosis of stromal
artery of ovary.
A study was conducted by Raja-Khan et
al (2011) in order to determine the effects of statins
on vascular performance, inflammation and blood
level of androgen among women suffering from
polycystic ovary syndrome. Of androgen hormones,
androstenedione exhibited a significant reduction
compared to atorvastatin and placebo4. However,
no significant difference was observed between the
two groups in our research. Androstenedione had
decreased significantly in the group where
participants had received atorvastatin. Hyper-
androgenomia is a risk factor that increases the
risk of affliction with cardio-vascular diseases and
high blood pressure among women with polycystic
ovary syndrome8. These are the Pleiotropic effect
of statin: improving the level of CRP, endothelial
performance disruption, higher bioavailability of
nitric oxide, antioxidant properties, harnessing
inflammatory responses, and stability of
Atherosclerotic plaques9. The level of DHEAS serum
and testosterone hormone among those suffering
from PCOS has been reported to be significantly
higher than what was observed among healthy
women10. Sathyapalan et al (2012) conducted a
research in order to see the effects of atorvastatin
on density of testosterone, androstenedione, DHEA,
and DHEAS among those suffering from PCOS. The
results reported a significant reduction of
androstenedione and DHEAS among those
patients who had received atorvastatin for 3 months.
However, no significant changes were observed
using the placebo11. It is important to keep in mind
that as the length of treatment becomes longer, it is
better to use a lower dose of this medicine and this
suggestion was followed and observed in other
researches conducted so far. Puurunen et al (2013)
studied the effects of atorvastatin treatment on
hormone parameters and metabolism of women
suffering from PCOS12. They reported a reduced
level of DHEAS serum in atorvastatin group while
no change was observed in the testosterone level
of serum. Meanwhile, the results of our research
indicated no decrease of these 2 parameters in
any of those two groups. Gao L et al13 conducted a
meta-analysis and reported a significant difference
in total reduction of testosterone serum while
comparing statin with placebo. This is quite the
opposite to the results we achieved in our research.
In another RCT research conducted on 248 women
suffering from PCOS in statin and placebo groups,
a reduction in the level of testosterone was
observed8.
According to the results of our research,
the changes in the average level of cholesterol and
LDL in both groups before and after intervention
were statistically significant and a higher level of
reduction was observed in atorvastatin group. Gao
L et al13 also believe that statin is more effective
than placebo in reducing the levels of LDL, TC and
TG. In the research conducted by Raval et al8, statins
helped improve the status of total cholesterol, LDL,
and TG, but they had no significant influence on
HDL, HS, and CRP. These results are so close to
the results we achieved. In our research, the HDL
level of patients before and after intervention in both
the placebo and atorvastatin group exhibited a
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significant increase. However, no significant
difference was observed between the two groups
before and after intervention in terms of changes in
the level of HDL. Changes in the level of TG were
not noticeable in any of these groups.
It was shown in another research that
using atorvastatin for 6 months helped reduce the
level of FBS and resistance against insulin12. Using
atorvastatin for 40 days in our research showed no
significant reduction in the level of fasting blood
Sugar. On the other hand, a significant reduction in
the level of fasting blood Sugar was observed
following treatment with atorvastatine in the
research conducted by Mobseri et al14.
The other two variables studied in this
research were size of ovary and resistance of ovary
artery. An increased size of ovary is one of the main
criteria used to diagnose polycystic ovary
syndrome15. As for the characteristics of this
syndrome in sonography, one may refer to an ovary
size above 10 cc and observation of 12 or more
Follicles in each ovary with a size of 2 to 9 mm and
stroma with increased central echo16. In our
research, the size of left and right ovaries exhibited
a statistically significant reduction in the group using
atorvastatin. However, no significant decrease in
the size of the ovaries was observed in the group
which had received placebo. All in all, the changes
in the size of the ovaries in case group was
significantly more than what was observed in
witness group which resulted in a statistically
significant size reduction. A research conducted in
2011 found no reduction in the size of ovary in any
of the two groups. A comparison of the average
changes in two groups reported no statistically
significant reduction in the size of the ovaries.
Keeping in mind the results of the current research
and the other research conducted in Pennsylvania,
measurement of size changes in larger samples
seems useful for recording more effective results
(4). No research on those suffering from PCOD was
found concerning the indexes of Doppler
sonography of stromal artery of ovary. A research
was conducted on 41 women with PCOD where
posterior cilliary artery, central retinal artery, and
orbital artery were studied and compared against
control group. Factors such as systolic and diastolic
pace had increased in orbital artery and posterior
cilliary artery, but arterial resistance index exhibited
some kind of reduction. They claimed a relationship
between the blood flow speed and levels of
cholesterol and a revers relationship between the
former and insulin and glucose level of serum17.
Although these researches did not deal with ovary
artery, the correlation between Doppler indexes and
systemic metabolic state points to the fact that the
very same study can be conducted for ovary artery.
In this research, a resistive index was taken from
both the case and Control groups and all of them
were above 0.40 which practically discarded any
possibility of malignant masses in ovaries as it has
been observed that tumoral arteries have no
muscular layer and they are of low resistance18.
Only RI was measured in our research. In another
RCT research, FMD (follow mediated dilation) in
brachial artery was measured. This value in internal
medicine is indicative of long-term cardiovascular
incidents. The results pointed to the fact that this
case caused no statistically significant change in
any one of the two groups. They claimed that the
average sum of FMD following consumption of
atorvastatin has improved, hence atorvastatin is a
useful medicine for these cardiovascular incidents4.
However, RI of stromal artery of ovary exhibited a
decrease in the mean on both sides. In statistical
terms, the resistance of right stromal artery exhibited
a borderline reduction. A statistically significant
difference was observed between the two groups
in terms of stromal arterial resistance of ovary
having eliminated the confounding influence of RI
variable. Considering the statistically significant
reduction in the average arterial resistance in case
group after receiving atorvastatin, this medicine
seems really helpful in fulfilling this goal. It is better
to study application of this medicine over a longer
course of time and in a larger population.
Concerning the Doppler indexes of the stromal
artery of ovary and consumption of metformin
among 25 women suffering from PCOS, RCT study
was carried out where they received a daily dose
of 850 mg of this medicine for 6 months which
resulted in the higher levels of RI and PI6.
Another method used to treat infertility
among those suffering from this syndrome is using
Diathermy or cauterization of the surface of ovary.
A research conducted on 52 patients 6 weeks after
laparoscopy and cauterization on Doppler indexes
of stromal artery of ovary demonstrated a greater
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pace of flow19. Using a non-invasive medical
treatment and without increasing the risk of surgical
side effects and early failure of ovary, favorable
therapeutic results may be achieved for a patient
using a method with good tolerance and little cost.
Research limitations
The small population of the patients due
to the strict exclusion criteria (using metformin
within the last three months before the research,
OCP, any anti-androgen medicines, cardio-vascular
diseases, gland and metabolism issues) was the
main limitation in this research. This problem can
be easily resolved by increasing the number of
participants.
CONCLUSION
All in all, we may conclude that atorvastatin
is a relatively useful medicine as it improves some
biochemical factors associated with metabolic
syndrome of these patients and its favorable
consequences on the artery of ovary can not be
denied. It is recommended to measure all Doppler
indexes on stromal artery of ovary so that more
accurate results can be achieved. Based on the
results achieved in our research, it is recommended
to carry out a study with a larger population where
indexes of stromal artery in patients suffering from
polycystic syndrome who are undergoing treatment
with atorvastatin can be studied in greater details
and the results can be used to treat the patients.
Keeping in mind the improvement of lipid profile
status and reduction of androstenedione levels
among those suffering from PCOS, atorvastatin can
be used as an auxiliary treatment to control the
symptoms and long-terms complications.
Concerning the reduction of the size of ovary and
improvement in blood flow of PCOS ovary, future
researches can focus on the effectiveness of statins
in improving the ovulation status and performance
of PCO ovaries.
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